articleThe LancetMar 17, 2013Closed access

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

CGCem GabayPEPaul EmeryRVRonald van VollenhovenADAra DikranianRARieke Alten

University Hospital of Geneva · University of Leeds · +4 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

668
total citations
FWCI
52.47
Percentile
100%
References
43
Citations per year

Authors

11

Topics & keywords

Topics
Keywords
  • Medicine
  • Tocilizumab
  • Adalimumab
  • Rheumatoid arthritis
  • Placebo
  • Internal medicine
  • Clinical endpoint
  • Methotrexate
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding